Agree but there are pending results from the Australia double blind and independent studies.....and the 50% CGT refund.
- Forums
- ASX - By Stock
- RAP
- Ann: ResApp Enrols First Patient in SMARTCOUGH-C-2 Study
Ann: ResApp Enrols First Patient in SMARTCOUGH-C-2 Study, page-7
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
Featured News
Add RAP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
BTH
BIGTINCAN HOLDINGS LIMITED
David Keane, Co-Founder & CEO
David Keane
Co-Founder & CEO
Previous Video
Next Video
SPONSORED BY The Market Online